Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the study drug.

Trial Details

NCT ID
NCT04165772
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • TSR-042 or Dostarlimab
  • capecitabine or 5-FU
  • Intensity Modulated Radiation Therapy (IMRT)
Locations (sample)
  • Hartford, Connecticut, United States|41.76371,-72.68509
  • Miami, Florida, United States|25.77427,-80.19366
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292

Key Eligibility Criteria

  • Willing and able to provide written informed consent for the trial.
  • Be ≥18 years of age on the date of signing informed consent.
  • ECOG performance status of 0 or 1.
  • Histologically confirmed locally advanced solid tumor (Cohorts 1 \& 2)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →